{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:09:44Z","timestamp":1787022584016,"version":"build-2736575974"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2020-0356_abs_001_w2aab3b7c48b1b6b1aab1c15b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Accurate management of metabolic decompensation in maple syrup urine disease (MSUD) has a crucial role, as acute attacks can cause neurological sequels and can be life threatening. Here, we aimed to evaluate effect of sodium phenylbutyrate (NaPBA) in acute management of MSUD attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2020-0356_abs_002_w2aab3b7c48b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Episodes with an initial plasma leucine (Leu) level above 750\u00a0\u00b5moL\/L and that require hospitalization due to clinical findings of Leu neurotoxicity and\/or feeding difficulties were included to the study. Patients who had no molecular diagnosis and a regular follow-up were excluded. Clinical findings, laboratory results and therapy responses were reviewed, retrospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2020-0356_abs_003_w2aab3b7c48b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten patients who experienced 19 distinct episodes of MSUD attacks were enrolled. Initial median Leu level was 901.67 (range 756\u20131989.11) and 33.9\u00a0\u00b5moL\/L (range 7.91\u2013347.3\u00a0\u00b5moL\/L) at the end of therapy. None of our patients underwent extracorporeal toxin removal during the course of attack. In patients with serial plasma quantitative amino acid sampling, mean Leu reduction rate was calculated to be 529.68\u00a0\u00b1\u00a0250.08\u00a0\u00b5moL\/L\/day at the 24th\u00a0h of treatment and 318.72\u00a0\u00b1\u00a0191.52\u00a0\u00b5moL\/L\/day at the 48th\u00a0h of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2020-0356_abs_004_w2aab3b7c48b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study is the first original study that investigates the effect of NaPBA in management of acute attacks of MSUD patients from Turkey. We suggest that NaPBA treatment in MSUD attacks can ameliorate clinical and biochemical findings. This therapeutic option should be considered especially in smaller centers without the toxin removal chance and for patients who were not appropriate for extracorporeal toxin removal like hemodynamic instability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2020-0356","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T03:00:54Z","timestamp":1605582054000},"page":"121-126","source":"Crossref","is-referenced-by-count":8,"title":["Impact of sodium phenylbutyrate treatment in acute management of maple syrup urine disease attacks: a single-center experience"],"prefix":"10.1515","volume":"34","author":[{"given":"Tanyel","family":"Zubarioglu","sequence":"first","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty , Department of Pediatrics Division of Nutrition and Metabolism , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Dede","sequence":"additional","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty , Department of Pediatrics , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humeyra","family":"Cigdem","sequence":"additional","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty , Department of Pediatrics Division of Nutrition and Metabolism , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertugrul","family":"Kiykim","sequence":"additional","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty , Department of Pediatrics Division of Nutrition and Metabolism , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet S.","family":"Cansever","sequence":"additional","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Central Laboratory , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Aktuglu-Zeybek","sequence":"additional","affiliation":[{"name":"Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty , Department of Pediatrics Division of Nutrition and Metabolism , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"2023040101232116941_j_jpem-2020-0356_ref_001_w2aab3b7c48b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Schiff, M, de Baulny, HO, Dionisi-Vici, C. Branched-chain organic acidurias\/acidaemias. In: Saudubray, JM, Baumgartner, MR, Walter, J, editors. Inborn metabolic diseases: diagnosis and treatment, 6th ed. Heidelberg: Springer-Verlag; 2016:279\u201388.","DOI":"10.1007\/978-3-662-49771-5_18"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_002_w2aab3b7c48b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Knerr, I, Vockley, J, Gibson, KM. Disorders of leucine, isoleucine, and valine metabolism. In: Blau, N, Duran, M, Gibson, KM, Dionisi-Vici, C, editors. Physician\u2019s guide to the diagnosis, treatment and follow-up of inherited metabolic diseases. Heidelberg: Springer-Verlag; 2014:103\u201343.","DOI":"10.1007\/978-3-642-40337-8_7"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_003_w2aab3b7c48b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Blackburn, PR, Gass, JM, Vairo, FPE, Farnham, KE, Atwal, HK, Macklin, S, et al.. Maple syrup urine disease: mechanisms and management. Appl Clin Genet 2017;10:57\u201366. https:\/\/doi.org\/10.2147\/tacg.s125962.","DOI":"10.2147\/TACG.S125962"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_004_w2aab3b7c48b1b6b1ab2b1b4Aa","unstructured":"Strauss, KA, Puffenberger, EG, Morton, DH. Maple syrup urine disease. In: Pagon, RAAdam, MP, Ardinger, HH, Wallace, SE, Bean, LJH, Stephens, K, et al.., editors. Gene reviews. Seattle (WASeattle): University of Washington; 2006:1993\u20132013 pp. (updated 2013 May 9)."},{"key":"2023040101232116941_j_jpem-2020-0356_ref_005_w2aab3b7c48b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Frazier, DM, Allgeier, C, Homer, C, Marriage, BJ, Ogata, B, Rohr, F, et al.. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metabol 2014;112:210\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2014.05.006.","DOI":"10.1016\/j.ymgme.2014.05.006"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_006_w2aab3b7c48b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Basseri, S, Lhot\u00e1k, S, Sharma, AM, Austin, RC. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. J Lipid Res 2009;50:2486\u2013501. https:\/\/doi.org\/10.1194\/jlr.m900216-jlr200.","DOI":"10.1194\/jlr.M900216-JLR200"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_007_w2aab3b7c48b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Iannitti, T, Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs RD 2011;11:227\u201349. https:\/\/doi.org\/10.2165\/11591280-000000000-00000.","DOI":"10.2165\/11591280-000000000-00000"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_008_w2aab3b7c48b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Scaglia, F, Carter, S, O\u2019Brien, WE, Lee, B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metabol 2004;81(1 Suppl):S79\u201385. https:\/\/doi.org\/10.1016\/j.ymgme.2003.11.017.","DOI":"10.1016\/j.ymgme.2003.11.017"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_009_w2aab3b7c48b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Burrage, LC, Jain, M, Gandolfo, L, Lee, BH. Members of the urea cycle disorders consortium, Nagamani SC. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol Genet Metabol 2014;113:131\u20135. https:\/\/doi.org\/10.1016\/j.ymgme.2014.06.005.","DOI":"10.1016\/j.ymgme.2014.06.005"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_010_w2aab3b7c48b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Brunetti-Pierri, N, Lanpher, B, Erez, A, Ananieva, EA, Islam, M, Marini, JC, et al.. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet 2011;20:631\u201340. https:\/\/doi.org\/10.1093\/hmg\/ddq507.","DOI":"10.1093\/hmg\/ddq507"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_011_w2aab3b7c48b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Puliyanda, DP, Harmon, WE, Peterschmitt, MJ, Irons, M, Somers, MJ. Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol 2002;17:239\u201342. https:\/\/doi.org\/10.1007\/s00467-001-0801-2.","DOI":"10.1007\/s00467-001-0801-2"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_012_w2aab3b7c48b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Strauss, KA, Carson, VJ, Soltys, K, Young, ME, Bowser, LE, Puffenberger, EG, et al.. Branched-chain \u03b1-ketoacid dehydrogenase deficiency (maple syrup urine disease): treatment, biomarkers, and outcomes. Mol Genet Metabol 2020;129:193\u2013206. https:\/\/doi.org\/10.1016\/j.ymgme.2020.01.006.","DOI":"10.1016\/j.ymgme.2020.01.006"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_013_w2aab3b7c48b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Jouvet, P, Jugie, M, Rabier, D, Desgres, J, Pubert, H, Saudubray, JM, et al.. Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease. Intensive Care Med 2001;27:1798\u2013806. https:\/\/doi.org\/10.1007\/s00134-001-1124-2.","DOI":"10.1007\/s00134-001-1124-2"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_014_w2aab3b7c48b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Phan, V, Clermont, MJ, Merouani, A, Litalien, C, Tucci, M, Lambert, M, et al.. Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model. Pediatr Nephrol 2006;21:698\u2013704. https:\/\/doi.org\/10.1007\/s00467-006-0044-3.","DOI":"10.1007\/s00467-006-0044-3"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_015_w2aab3b7c48b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Demirkol, D, \u015e\u0131k, G, Topal, N, \u00c7\u0131tak, A, Zeybek, \u00c7, T\u00fcten, A, et al.. Continuous venovenous hemodiafiltration in the treatment of maple syrup urine disease. Blood Purif 2016;42:27\u201332. https:\/\/doi.org\/10.1159\/000443783.","DOI":"10.1159\/000443783"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_016_w2aab3b7c48b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Wynn, RM, Kato, M, Machius, M, Chuang, JL, Li, J, Tomchick, DR, et al.. Molecular mechanism for regulation of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase complex by phosphorylation. Structure 2004;12:2185\u201396. https:\/\/doi.org\/10.1016\/j.str.2004.09.013.","DOI":"10.1016\/j.str.2004.09.013"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_017_w2aab3b7c48b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Tso, SC, Qi, X, Gui, WJ, Chuang, JL, Morlock, LK, Wallace, AL, et al.. Structure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain \u03b1-ketoacid dehydrogenase kinase. Proc Natl Acad Sci U S A 2013;110:9728\u201333. https:\/\/doi.org\/10.1073\/pnas.1303220110.","DOI":"10.1073\/pnas.1303220110"},{"key":"2023040101232116941_j_jpem-2020-0356_ref_018_w2aab3b7c48b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"K\u00f6se, M, Canda, E, Kagnici, M, U\u00e7ar, SK, \u00c7oker, M. A patient with MSUD: acute management with sodium phenylacetate\/sodium benzoate and sodium phenylbutyrate. Case Rep Pediatr 2017;2017:1045031. https:\/\/doi.org\/10.1155\/2017\/1045031.","DOI":"10.1155\/2017\/1045031"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpem\/34\/1\/article-p121.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0356\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T15:57:00Z","timestamp":1680364620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0356\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,12]]},"published-print":{"date-parts":[[2021,1,27]]}},"alternative-id":["10.1515\/jpem-2020-0356"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0356","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,11]]}}}